Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 79 for “"raloxifene"”.
-
Raloxifene and tibolone in elderly women.
Contains fulltext : 97288.pdf (Publisher’s version ) (Open Access)
-
The Effects of Zoledronate and Raloxifene Combination Therapy on Diseased Mouse Bone
… shown to compromise bone quality. Alternatively, Raloxifene (RAL) has recently been demonstrated to improve tissue quality and overall mechanical properties by binding to collagen and increasing tissue hydration in a cell-independent manner. We hypothesized that a combination of RAL and ZOL would …
-
Formulation and Characterization of Raloxifene Nanostructured Lipid Carries for Permeability Enhancement Applications
Raloxifene (RLX), a BCS class-II drug is a selective estrogen receptor modulator (SERM)having estrogenic effect on bone and antiestrogenic effect on endometrium and breast respectively. Low solubility, high permeability, high metabolism and low bioavailability are the characteristics of raloxifene. …
-
Continuous Production Of Raloxifene Hydrochloride Loaded Nanostructured Lipid Carriers Using Hot-Melt Extrusion Technology
… a continuous process for the production of Raloxifene Hydrochloride (RX-HCl) loaded NLC formulations for extended drug release using hot-melt extrusion technology coupled with probe sonication, and also to evaluate the in vitro characteristics of the prepared NLCs by particle size, PDI, zeta …
-
IMMUNOMODULATORY ACTIVITY OF TAMOXIFEN AND RALOXIFENE IN MACROPHAGES: IMPLICATIONS FOR HOST-DIRECTED THERAPIES IN INFECTIOUS DISEASES
Tamoxifene (TAM) e raloxifene (RAL) sono modulatori selettivi del recettore degli estrogeni (SERMs), ampiamente prescritti per il trattamento di patologie dipendenti dal recettore degli estrogeni α (ERα), come il tumore al seno ERα-positivo e l’osteoporosi. Recentemente, questi farmaci hanno …
-
Relationships between circulating hormones and brain abnormalities in schizophrenia and restoration of brain activity by raloxifene treatment
… with a brain estrogen receptor agonist, raloxifene, could enhance neural activation during facial emotion recognition in patients. Raloxifene increased prefrontal and hippocampal activation during emotion recognition in males and females with schizophrenia, demonstrating the drug s …
-
The effects of the selective estrogen receptor modulators MPP and raloxifene in normal and cancerous human and murine uterine tissue
… (SERMs), methyl-piperidino-pyrazole (MPP), raloxifene, ICI 182,780 and 17[beta]-estradiol on endometrial carcinoma cells in culture and on murine uterine tissue. These SERMs have been developed to target and understand the role of estrogen receptor action in estrogen-responsive organs. Based …
-
Thermoneutral Housing Did Not Impact the Combined Effects of External Loading and Raloxifene on Bone Morphology and Mechanical Properties in Growing Female Mice
Raloxifene is an FDA-approved selective estrogen receptor modulator (SERM) that improves tissue quality by binding to collagen and increasing the bound water content in the bone matrix in a cell-independent manner. In this thesis, active tissue formation was induced by non-invasive external tibial …
-
Sex-specific characterisation of neuroinflammatory and stress-related mechanisms associated with dopamine dysregulation in schizophrenia
… the selective estrogen receptor (ER) modulator, raloxifene, alters DA-related behaviour and gene and protein expression within the SN of adult rats exposed to a prenatal immune stressor. I characterise sex-specific effects of raloxifene on stress-, ER, and neuroinflammatory-related transcripts …
-
Economic evaluation of three preventive drug therapies for osteoporotic fractures among women at different risk levels
… replacement therapy (HRT), alendronate, and raloxifene. Methods. A hypothetical cohort of white women aged 45--85 years, postmenopausal, and without past incidence of osteoporotic fractures was treated with one of the three alternatives, and tracked over 3 years in a decision model. The CE …
-
Η επίδραση της ορμονικής θεραπείας, της ραλοξιφαίνης και της τιβολόνης στη μαστογραφική πυκνότητα: συσχέτιση με τα ενδογενή στεροειδή του φύλου, τα λιπίδια του πλάσματος και τον ινσουλινομιμητικό αυξητικό παράγοντα (IGF)
… therapy regimens (estrogens and progestins) raloxifene and tibolone, on mammographic breast density and its correlation with endogenous sex hormones, plasm fats and insulin-like growth factor in postmenopausal women. Methods: Two hundred and sixty-eight postmenopausal women, were studied …
-
Searching for novel ligands for the cannabinoid and related receptors.
… CB2. Among the 640 FDA-approved drugs screened, raloxifene, a drug used to treat/prevent post-menopausal osteoporosis, was identified for the first time to be a novel CB2 inverse agonist. The dissertation reporting these results demonstrated that by acting on CB2, raloxifene enhances …
-
Alterations In Tissue Composition And Nanomechanical Properties With Ageing, Osteoporosis, And Treatment
… endogenous estrogen receptor pathways in bone, raloxifene (a selective estrogen receptor modulator, SERM). zoledronate was most effective in cancellous rather than cortical tissue and provided the greatest increases (relative to osteoporotic tissue) in stiffness, hardness, and mineralization at …
-
Η επίδραση της ορμονικής θεραπείας, της τιβολόνης και της ραλοξιφαίνης στην έκφραση της επιθηλιακής καντχερίνης και του αγγειοενδοθηλιακού αυξητικού παράγοντα σε τραχηλικά επιθηλιακά κύτταρα μετεμμηνοπαυσιακών γυναικών
… expression and hormone therapy (HT), tibolone or raloxifene in cervical epithelial cells from postmenopausal women. Secondarily, to evaluate the possible role of reproductive, lifestyle and hormonal factors in their presence. Given that E-cadherin and VEGF are expressed aberrantly during cervical …
-
Improving the effect of primary care physicians on uptake of chemoprevention in women at high risk of breast cancer
… of invasive breast cancers by up to 49%. Raloxifene is as effective at preventing invasive breast carcinoma. Despite being approved for use in breast cancer prevention by the Federal Drug Administration in 1998, tamoxifen is infrequently used by eligible women. Approximately 10 million …
-
Joint Intervention in Opposing Pathways, PI3K/Akt and TGF-beta, with PX-866 and Raloxifene, to Alter Gene Expression and Suppress Estrogen Receptor-positive Breast Cancer Cell Proliferation
… diseases. Accordingly, I tested the effects of raloxifene to up-regulate the TGF-beta pathway in combination with PX-866 to down-regulate the PI3K/Akt pathway in estrogen receptor expressing MCF-7 breast cancer cells. I evaluated upstream and downstream effects that led to decreased cell cycle …
Page 1 of 4